Hepatic steatosis: Prevalence and host/viral risk factors in iranian patients with chronic hepatitis B infection

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 9, 2014, Pages 3879-3884

  Poortahmasebi, Vahdat ^a   Alavian, Seyed Moayed ^b   Keyvani, Hossein ^c   Norouzi, Mehdi ^a   Mahmoodi, Mahmood ^d   Jazayeri, Seyed Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Middle East Liver Diseases Center (MELD Centers)   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Fibrosis; HBV; Host factors; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL; GLUCOSE BLOOD LEVEL; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGE; BLOOD; BODY MASS; COMPARATIVE STUDY; FATTY LIVER; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IRAN; LIVER CIRRHOSIS; MALE; PATHOLOGY; RISK FACTOR; SEX DIFFERENCE; VIROLOGY; VIRUS LOAD;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; DNA, VIRAL; FATTY LIVER; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IRAN; LIVER CIRRHOSIS; MALE; RISK FACTORS; SEX FACTORS; VIRAL LOAD;

EID: 84902683079     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.9.3879     Document Type: Article

References (43)

1. Altlparmak E, Koklu S, Yalinkilic M, et al (2005). Viral and host causes of fatty liver in chronic hepatitis B. World J Gastroenterol, 11, 3056-9.
2. Ates F, Yalniz M, Alan S (2011). Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B. World J Gastroenterol, 17, 4517-22.
3. Bach N, Thung SN, Schaffner F (1992). The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology, 15, 572-7.
4. Basaranoglu M, Basaranoglu G (2011). Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol, 17, 4055-62.
5. Bondini S, Kallman J, Wheeler A, et al (2007). Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int, 27, 607-11.
6. Bugianesi E (2007). Non-alcoholic steatohepatitis and cancer. Clin Liver Dis, 11, 191-207.
7. Cindoruk M, Karakan T, Unal S (2007). Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol, 41, 513-7.
8. Fujie H, Yotsuyanagi H, Moriya K, et al (1999). Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol, 59, 141-5.
9. Gordon A, Mclean CA, Pedersen JS, Bailey MJ, Roberts SK (2005). Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol, 43, 38-44.
10. Harrison SA, Brunt EM, Qazi RA, et al (2005). Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol, 3, 604-9.
11. Jiang J, Nilsson-Ehle P, Xu N (2006). Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis, 5, 4.
12. Jin X, Chen YP, Yang YD, et al (2012). Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One, 7, 34198.
13. Kim JY, Song EH, Lee HJ, et al (2010). HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J Mol Biol, 397, 917-31.
14. Kim KH, Shin HJ, Kim K, et al (2007). Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology, 132, 1955-67.
15. Kim YC, Song KS, Yoon G, Nam MJ, Ryu WS (2001). Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis. Oncogene, 20, 16-23.
16. Lagging LM, Garcia CE, Westin J, et al (2002). Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. J Clin Microbiol, 40, 4224-9.
17. Lesmana LA, Lesmana CR, Pakasi LS, Krisnuhoni E (2012). Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. Acta Med Indones, 44, 35-9.
18. Lonardo A, Adinolfi LE, Loria P, et al (2004). Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology, 126, 586-97.
19. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G (2006). Hepatitis C and steatosis: a reappraisal. J Viral Hepat, 13, 73-80.
20. Malhotra V, Sakhuja P, Gondal R, et al (2000). Histological omparison of chronic hepatitis B and C in an Indian population. Trop Gastroenterol, 21, 20-1.
21. Matteoni CA, Younossi ZM, Gramlich T, et al (1999). Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 116, 1413-9.
22. Minakari M, Molaei M, Shalmani HM, et al (2009). Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. Eur J Gastroenterol Hepatol, 21, 512-6.
23. Na TY, Shin YK, Roh KJ, et al (2009). Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology, 49, 1122-31.
24. Nascimento AC, Maia DR, Neto SM, et al (2012). Nonalcoholic Fatty liver disease in chronic hepatitis B and C patients from Western Amazon. Int J Hepatol, 2012, 695950.
25. Peng D, Han Y, Ding H, Wei L (2008). Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol, 23, 1082-8.
26. Petta S, Camma C, Di Marco V, et al (2011). Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int, 31, 507-15.
27. Powell EE, Jonsson JR,Clouston AD (2005). Steatosis: co-factor in other liver diseases. Hepatology, 42, 5-13.
28. Rastogi A, Sakhuja P, Kumar A, et al (2011). Steatosis in chronic hepatitis B: prevalence and association with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol, 54, 454-9.
29. Ratziu V, Trabut JB, Poynard T (2004). Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep, 6, 22-9.
30. Roberts JM, Searle JW, Cooksley WG (1993). Histological patterns of prolonged hepatitis C infection. Gastroenterol Jpn, 28, 37-41.
31. Sass DA, Chang P, Chopra KB (2005). Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci, 50, 171-80.
32. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko G M (1992). The pathology of hepatitis C. Hepatology, 15, 567-71.
33. Schiff ER, Sorell MF, WC M (1999). Disease of the Liver., Philedelphia: Lippincot-Williams and Wilkins.
34. Shi JP, Fan JG, Wu R, et al (2008). Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol, 23, 1419-25.
35. Starley BQ, Calcagno CJ, Harrison SA (2010). Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, 51, 1820-32.
36. Thomopoulos KC, Arvaniti V, Tsamantas AC, et al (2006). Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol, 18, 233-7.
37. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al (2007). Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Dig Liver Dis, 39, 936-42.
38. Walsh MJ, Vanags DM, Clouston AD, et al (2004). Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology, 39, 1230-8.
39. Wan G, Ohnomi S, Kato N (2000). Increased hepatic activity of inducible nitric oxide synthase in rats fed on a high-fat diet. Biosci Biotechnol Biochem, 64, 555-61.
40. Yang S, Lin H, Diehl AM (2001). Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol, 281, 382-92.
41. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM (1997). Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA, 94, 2557-62.
42. Yoon EJ, Hu KQ (2006). Hepatitis C virus (HCV) infection and hepatic steatosis. Int J Med Sci, 3, 53-6.
43. Zheng RD, Xu CR, Jiang L, et al (2010). Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. Int J Med Sci, 7, 272-7.